Related content

Alogliptin benzoate for the treatment of type 2 diabetes

By Rendell Marc   Drincic Andjela   Andukuri Radha  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 4, 2012-03 ,pp. : 553-563

Informa Healthcare

Access to resources Recommend Favorite

Alogliptin alleviates type 2 diabetes burden

By  

Inpharma, Vol. 1, Iss. 1643, 2008-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

By Pratley Richard E  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 3, 2009-02 ,pp. : 503-512

Informa Healthcare

Access to resources Recommend Favorite

Alogliptin: A Review of its Use in the Management of Type 2 Diabetes Mellitus

By Scott Lesley J.  

Drugs, Vol. 70, Iss. 15, 2010-10 ,pp. : 2051-2072

Adis International

Access to resources Recommend Favorite

Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors

By Masuda Kiyomi   Aoki Kazutaka   Kamiko Kazunari   Takihata Masahiro   Ito Yuzuru   Nagakura Mieko   Kawasaki Satsuki   Akema Noriko   Hasegawa Maki   Nakajima Shigeru   Shinoda Kazuaki   Toumura Shyoken   Tsunoda Seishi   Enomoto Hitoshi   Shimotomai Hidefumi   Terauchi Yasuo  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1111-1118

Informa Healthcare

Access to resources Recommend Favorite